28 We and others have recently reported the therapeutic efficacy of combined use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib for cancer treatments, including both BRCA1-proficient and -deficient breast cancer,29 PTEN-deficient prostate cancer,30 as well as ovarian cancer31, 32 and lung cancer.33 Meanwhile, the therapeutic strategy of using combined BKM120/Olaparib is being tested in a Phase I clinical trial in patients with recurrent triple negative breast cancer and high-grade serous ovarian cancer (www.clinicaltrials.gov). Here, PTEN is linked to cancer.